A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Eligible age
18+ yrs
Accepts
All genders
Locations
22 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Sponsor: Eli Lilly and Company
You may qualify if…
- ✓ Have a diagnosis of moderate-to-severe plaque PsO, as defined by a dermatologist or other experienced clinician treated PsO (for example, allergologist, nurse practitioner or physician assistant)
- ✓ Have body mass index (BMI) of 30 kilograms per meter squared (kg/m²) or greater (obesity) or 27 kg/m² to \<30 kg/m² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular diseases).
- ✓ Must have initiated treatment with ixekizumab for approximately 3 months (± 1 month) prior to decision to add tirzepatide.
- ✓ Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline/screening).
You may not qualify if…
- ✕ Have currently received ixekizumab for more than 4 months or less than 2 months.
- ✕ Have had any exposure to tirzepatide or other glucagon-like peptide-1 receptor agonist (GLP-1 RAs), for example, dulaglutide, liraglutide, or semaglutide.
- ✕ Are currently enrolled in any other clinical study.
- ✕ Other exclusions
- ✕ Have a known hypersensitivity to tirzepatide or to any of its component.
- ✕ Have a personal or family history of medullary thyroid cancer.
- ✕ Have multiple endocrine neoplasia type 2.
- ✕ Have type I diabetes mellitus.
Where it's recruiting
Phoenix
Fountain Valley · Fremont · Los Angeles · Northridge
Hialeah · Hollywood · Tampa · Wellington
Douglasville
Indianapolis · Plainfield
Bowling Green
Rockville
Brighton
Ann Arbor · Bay City · Caledonia
Reno
Portsmouth
East Windsor · Hoboken
Source: ClinicalTrials.gov · NCT06857942 · last updated 2026-06-03